By Ecosystem-
By Application-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Precision Oncology Market Snapshot
Chapter 4. Global Precision Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Ecosystem Estimates & Trend Analysis
5.1. by Ecosystem & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Ecosystem:
5.2.1. Precision Therapeutics
5.2.1.1. Clinical Trials
5.2.1.2. Biomarker Testing
5.2.1.3. Drug Discovery and Research
5.2.1.4. Gene Therapy
5.2.1.5. Cell Therapy
5.2.2. Applied Sciences
5.2.2.1. Genomics
5.2.2.1.1. Polymerase Chain Reaction (PCR)
5.2.2.1.2. Precision Medicine Next-Generation Sequencing
5.2.2.1.3. Genome Editing
5.2.2.1.4. Other Technologies
5.2.2.2. Pharmacogenomics
5.2.2.3. Other Applied Sciences
5.2.3. Digital Health and Information Technology
5.2.3.1. Clinical Decision Support System (CDSS)
5.2.3.2. Big Data Analytics
5.2.3.3. IT Infrastructure
5.2.3.4. Genomics Informatics
5.2.3.5. In-Silico Informatics
5.2.3.6. Mobile Health
5.2.4. Precision Diagnostics
5.2.4.1. Molecular Diagnostics (MDx)
5.2.4.2. Medical Imaging
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Solid Tumor
6.2.1.1. Breast Cancer
6.2.1.2. Lung Cancer
6.2.1.3. Colorectal Cancer
6.2.1.4. Prostate Cancer
6.2.1.5. Cervical Cancer
6.2.1.6. Other Cancer
6.2.2. Hematological Malignancies (HMs)
6.2.2.1. Leukemia
6.2.2.2. Lymphoma
6.2.2.3. Myeloma or Multiple Myeloma (MM)
6.2.2.4. Other Hematological Malignancies
Chapter 7. Precision Oncology Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Ecosystem, 2023-2031
7.1.2. North America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.1.3. North America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.2. Europe
7.2.1. Europe Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Ecosystem, 2023-2031
7.2.2. Europe Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.2.3. Europe Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Ecosystem, 2023-2031
7.3.2. Asia Pacific Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.3.3. Asia Pacific Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.4. Latin America
7.4.1. Latin America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Ecosystem, 2023-2031
7.4.2. Latin America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.4.3. Latin America Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Ecosystem, 2023-2031
7.5.2. Middle East & Africa Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.5.3. Middle East & Africa Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Abbott Laboratories
8.2.2. Acrivon Therapeutics
8.2.3. Agilent Technologies, Inc.
8.2.4. Almac Group Ltd.
8.2.5. AstraZeneca
8.2.6. ASURAGEN, INC.
8.2.7. BGI Group
8.2.8. Bio-Rad Laboratories, Inc.
8.2.9. Bioserve
8.2.10. Bristol-Myers Squibb
8.2.11. Eli Lilly
8.2.12. Exact Sciences Corporation
8.2.13. F Hoffmann-La Roche AG
8.2.14. Gilead Sciences, Inc.
8.2.15. Illumina, Inc.
8.2.16. Invitae Corporation
8.2.17. Laboratory Corporation Of America Holding
8.2.18. MDxHealth
8.2.19. Myriad Genetics, Inc.
8.2.20. Novartis AG
8.2.21. OPKO Health, Inc.
8.2.22. Pacific Biosciences of California, Inc.
8.2.23. PerkinElmer Inc.
8.2.24. Qiagen N.V.
8.2.25. Quest Diagnostics Incorporated
8.2.26. Rain Oncology Inc.
8.2.27. Relay Therapeutics
8.2.28. Strata Oncology, Inc.
8.2.29. Thermo Fisher Scientific Inc.
8.2.30. Variantyx, Inc.
8.2.31. Xilis, Inc.
8.2.32. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.